Relay Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Relay Therapeutics, Inc. on September 7, 2022. The report discloses a late-breaking abstract regarding interim clinical data from the Company's ReFocus trial for RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial disclosures and does not contain financial statements or performance metrics.
Material Changes
The material event reported is the publication of an abstract on the European Society for Medical Oncology (ESMO) website. The abstract details interim data for RLY-4008 in patients with FGFR2-fusion or rearrangement, FGFR inhibitor-naïve cholangiocarcinoma. The abstract has been selected for an oral presentation at the ESMO Congress 2022.
Outlook, Commentary, and Risks
- Upcoming Events: The Company plans to issue a press release announcing the interim clinical data on September 11, 2022, during the ESMO Congress.
- Investor Communication: A conference call and live webcast are scheduled for September 12, 2022, at 8:00 am E.T.
- Legal Status: The information in Item 7.01 and Exhibit 99.1 is furnished and not deemed "filed" under Section 18 of the Exchange Act, nor is it incorporated by reference into other filings except as expressly set forth.
Key Facts for Investor Verification
- Verify the full text of the abstract attached as Exhibit 99.1 for specific efficacy data points.
- Confirm the date and time of the upcoming press release (September 11, 2022) and conference call (September 12, 2022).
- Note that this filing does not contain updated financial guidance or balance sheet information.